Mechanisms of Resistance to Anti-angiogenic Treatments

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582580

Authors

Francesco Pezzella

Affiliations

Soon will be listed here.

Abstract

Hailed as the cancer treatment to end all the resistance to treatment, anti-angiogenic therapy turned out to be not quite what was promised. The hope that this therapeutic approach would not have suffered by the phenomenon of resistance was based on the fact that was targeting normal vessels rather than tumour cells prone to mutation and subject to drug induced selection. However, reality turned out to be more complex and since 1997, several mechanisms of resistance have been described to the point that the study of resistance to these drugs is now a very large field. Far from being exhaustive, this paper presents the main mechanisms discovered trough some examples.

Citing Articles

In Vitro Cytotoxic Potential and In Vivo Antitumor Effects of NOS/PDK-Inhibitor T1084.

Filimonova M, Shitova A, Shevchenko L, Soldatova O, Surinova V, Rybachuk V Int J Mol Sci. 2024; 25(17).

PMID: 39273658 PMC: 11396549. DOI: 10.3390/ijms25179711.

Vascular co-option in resistance to anti-angiogenic therapy.

Ribatti D, Annese T, Tamma R Front Oncol. 2023; 13:1323350.

PMID: 38148844 PMC: 10750409. DOI: 10.3389/fonc.2023.1323350.

Editorial: Vascular co-option and beyond for cancer biology.

Pezzella F, Qian C Front Oncol. 2023; 13:1227540.

PMID: 37456261 PMC: 10338838. DOI: 10.3389/fonc.2023.1227540.

Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy.

Hoffmann E, Gerwing M, Krahling T, Hansen U, Kronenberg K, Masthoff M Breast Cancer Res. 2023; 25(1):56.

PMID: 37221619 PMC: 10207609. DOI: 10.1186/s13058-023-01658-9.

Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies.

Pezzella F, Ribatti D Cancer Rep (Hoboken). 2020; 5(12):e1318.

PMID: 33295149 PMC: 9780428. DOI: 10.1002/cnr2.1318.

References

Kerr R, Love S, Segelov E, Johnstone E, Falcon B, Hewett P . Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncol. 2016; 17(11):1543-1557. DOI: 10.1016/S1470-2045(16)30172-3. View

Aird W . Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007; 100(2):158-73. DOI: 10.1161/01.RES.0000255691.76142.4a. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Manzo A, Montanino A, Carillio G, Costanzo R, Sandomenico C, Normanno N . Angiogenesis Inhibitors in NSCLC. Int J Mol Sci. 2017; 18(10). PMC: 5666703. DOI: 10.3390/ijms18102021. View

Takahashi Y, Kitadai Y, Bucana C, Cleary K, Ellis L . Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995; 55(18):3964-8. View

Yu J, Rak J, Coomber B, Hicklin D, Kerbel R . Effect of p53 status on tumor response to antiangiogenic therapy. Science. 2002; 295(5559):1526-8. DOI: 10.1126/science.1068327. View

Colpaert C, Vermeulen P, Van Beest P, Soubry A, Goovaerts G, Dirix L . Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition. Histopathology. 2003; 42(6):530-40. DOI: 10.1046/j.1365-2559.2003.01629.x. View

Frentzas S, Simoneau E, Bridgeman V, Vermeulen P, Foo S, Kostaras E . Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med. 2016; 22(11):1294-1302. PMC: 5104270. DOI: 10.1038/nm.4197. View

Poon E, Harris A, Ashcroft M . Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med. 2009; 11:e26. DOI: 10.1017/S1462399409001173. View

10.

Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D . Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003; 63(21):7400-9. View

11.

Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T . Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology. 1996; 23(3):455-64. DOI: 10.1053/jhep.1996.v23.pm0008617424. View

12.

Ribatti D . Tumor refractoriness to anti-VEGF therapy. Oncotarget. 2016; 7(29):46668-46677. PMC: 5216828. DOI: 10.18632/oncotarget.8694. View

13.

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View

14.

Nakajima E, Van Houten B . Metabolic symbiosis in cancer: refocusing the Warburg lens. Mol Carcinog. 2012; 52(5):329-37. PMC: 9972501. DOI: 10.1002/mc.21863. View

15.

Ward C, Langdon S, Mullen P, Harris A, Harrison D, Supuran C . New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev. 2012; 39(2):171-9. DOI: 10.1016/j.ctrv.2012.08.004. View

16.

Ferrara N, Henzel W . Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989; 161(2):851-8. DOI: 10.1016/0006-291x(89)92678-8. View

17.

Kuczynski E, Vermeulen P, Pezzella F, Kerbel R, Reynolds A . Vessel co-option in cancer. Nat Rev Clin Oncol. 2019; 16(8):469-493. DOI: 10.1038/s41571-019-0181-9. View

18.

Stratigos M, Matikas A, Voutsina A, Mavroudis D, Georgoulias V . Targeting angiogenesis in small cell lung cancer. Transl Lung Cancer Res. 2016; 5(4):389-400. PMC: 5009078. DOI: 10.21037/tlcr.2016.08.04. View

19.

Bussolati B, Assenzio B, Deregibus M, Camussi G . The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. J Mol Med (Berl). 2006; 84(10):852-63. DOI: 10.1007/s00109-006-0075-z. View

20.

Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G . Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol. 1997; 151(5):1417-23. PMC: 1858069. View